News & Updates

February 2021

Our affiliate Prestige Biologics fixed public offering price at KRW12,400.


February 26 2021 Prestige Biologics announced on the 26th that as a result of conducting a demand forecast for institutional investors on the 23rd and 24th, the public offering price has confirmed at the top of the price range of KRW 12,400.

Prestige Biologics conducted a stock allocation demand survey on 5,512,500 in shares, 75% of the total shares (7,350,000). According to Mirae Asset Daewoo, which is in charge of the listing, a total of 864 organizations, including most major domestic and overseas asset management companies, participated, and among them, 99.7% of the participation rate above the top of the price range. In addition, the competition rate was 369.91 to 1.






Prestige Biologics is scheduled to be listed in March after offering to general investors of 1,837,500 shares, which is 25% of the total volume from March 2 to 3.

Prestige Biologics has built up infrastructure such as GMP production facilities and quality systems for global biopharmaceutical CDMO business and has established production-oriented technology capabilities.

The second factory is being built with the 'Alita' system, which is a self-developed smart factory manufacturing method. It is expected to complete in 2022, the company's total production capacity is expected to increase to 104,000 liters, will lead to global top-tier CDMO company.




February 2021

Change of Stock name from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’.

February 5 2021 Prestige Biopharma Ltd. (PBP), specializing in the development of new antibody therapeutics and biosimilars, officially announced on February 24, 2021 that their stock name will be changed from ‘PBPharma’ to ‘PRESTIGE BIOPHARMA’ as of March 2, 2021.
This change aims “to standardize our stock name with Prestige Biologics Co., Ltd. scheduled to be listed on KOSDAQ next month and provide a clear understanding of each company’s business areas”, according to the official. The company added that “we sincerely appreciate the investors’ interest and will make every effort to take responsibility as a listed company and add long-term value to the company by focusing on the development of biosimilars and new antibody therapeutics”.
PBP has been listed on the KOSPI market on February 5, 2021 and ‘PRESTIGE BIOPHARMA’ will be indicated as its stock name from March 2, 2021. The affiliated manufacturing company, Prestige Biologics Co., Ltd. is also slated to be listed on KOSDAQ with its stock name, ‘PRESTIGE BIOLOGICS’.
PBP is a Singapore based biopharmaceutical company developing eight biosimilars and two new antibody therapeutics and its IPO fund will be invested in R&D, facilities and penetrating the global pharmaceutical market. The company is currently working on the marketing authorization approval of its trastuzumab biosimilar to Herceptin (HD201), the marketing authorization application of its Bevacizumab biosimilar to Avastin (HD204) and the clinical development of an innovative anti-PAUF mAb (PBP1510) and an Adalimumab biosimilar (PBP1502).
With the opening of Prestige Biopharma Advanced Research Center (ARC) next month in Boston, USA, PBP will also expand their focus to develop new anti-cancer drugs and Coronavirus vaccines and treatments.

February 2021

Tabuk Pharmaceuticals Partners with Prestige BioPharma for commercialization of Tuznue Trastuzumab Biosimilar in MENA

February 13, 2021, Tuznue™ is a mAb biosimilar to Roche's Herceptin® (trastuzumab), which is used to treat patients with HER2-overexpressing breast cancer and HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma.
February 2021

Prestige Biopharma raises 453 billion won from Korean IPO

Please the Close Pop Up when you open the link
February 8, 2021,
SINGAPORE-BASED biotech firm Prestige Biopharma has raised net proceeds of 453 billion won (S$539.9 million) from an initial public offering (IPO) on the Korea Exchange.
February 2021

Due to character limit at Korea Exchange, Prestige Biopharma has been listed as PB PHARMA (950210). Please note the code no 950210.

February 5 2021 Prestige Biopharma (Ticker code: 950210, CEO Lisa Park) has been listed on the KOSPI with the stock symbol "PB PHARMA (950210) An official from Prestige Biopharma said, "to be in compliance with stock exchange guidance, where the stock symbol is limited up to 6 Korean alphabets, the stock symbol has been changed from Prestige Biopharma (950210) to “PB PHARMA (950210)", so as to avoid any confusion for investors.
January 2021


Prestige Biopharma eyes at least 1.8t won valuation in Korean IPO

January 20, 2021 SINGAPORE-BASED Prestige Biopharma expects an implied market capitalisation of between 1.8 trillion won and 1.93 trillion won (S$2.2 billion to S$2.3 billion) in its upcoming initial public offering (IPO) on the Korea Exchange (KRX), the company told The Business Times.
January 2021


Will Prestige BioPharma's upcoming IPO continue frenzy in bio market?

January 18, 2021 Singapore-headquartered Prestige BioPharma, a biopharmaceutical company focusing on the development of biosimilars and new antibody therapeutics, is set for initial public offering (IPO) on the nation's main benchmark KOSPI early next month.
January 2021


Singapore-based Prestige Biopharma is in the midst of pursuing an IPO on the Korea Exchange, with targeted listing early this year

December 2020


Near-unicorn Prestige Biopharma eyes early-2021 IPO in South Korea

December 12, 2020 Singapore-based Prestige BioPharma is in the midst of pursuing an initial public offering (IPO) on the Korea Exchange, with a targeted listing in early 2021.
November 2020


Prestige Biopharma and Teva Israel Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar (Tuznue™) in Israel

November 10, 2020 Prestige BioPharma Ltd. and Abic Marketing Ltd. (operates under the brand of Teva Israel, hereinafter "Teva Israel"), a subsidiary of Teva Pharmaceutical Industries Ltd. announced today that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma's Trastuzumab biosimilar (HD201; Tuznue™) in Israel.
September 2020


Prestige BioPharma Presents Positive Top-Line Results from Phase III and New Data from 3-Arm Phase I Bridging Study for HD201 (Trastuzumab Biosimilar)

September 23, 2020 Prestige BioPharma announced positive top-line results from a Phase III global clinical trial have been presented in an oral presentation at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 on September 18, 2020.

These top-line results, which confirm no clinically significant differences between HD201 and the originator product Herceptin®, demonstrate HD201’s exceptional similarity to Herceptin® in terms of clinical response and pharmacokinetics (PK), in addition to a comparable safety profile to the range previously observed in other trastuzumab biosimilar clinical trials.

Prestige BioPharma also reported that new data from the 3-Arm Phase I Bridging Study have been selected for a poster presentation during the virtual congress on September 17, 2020. The data includes results from a total of 105 healthy male subjects in the 3 arms, in which HD201 demonstrates equivalent PK to both EU-Herceptin® and US-Herceptin®.
June 2020


US FDA Grants Orphan Drug Designation (ODD) for Prestige BioPharma’s PBP1510 Anti-PAUF Monoclonal Antibody for the Treatment of Pancreatic Cancer

June 30, 2020 Prestige BioPharma Ltd. (hereinafter “Prestige BioPharma”) today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its first-in-class anti-PAUF monoclonal antibody, PBP1510, for the treatment of pancreatic cancer.
November 2019



Prestige Biopharma at CPhI Worldwide 2019 in Frankfurt, Germany


November 7, 2019 This year's CPhI Worldwide has just concluded and we met with fellow pharmaceutical industry movers and stakeholders. Thank you for visiting Prestige at CPhI Worldwide.
August 2019

Prestige Biopharma partners with Huons to market three key biosimilars in South Korea


August 28, 2019 Prestige BioPharma announced that Prestige and Huons have entered into an exclusive partnership for the commercialization of three key biosimilars in South Korea.
July 2019

Prestige Biopharma and Pharmapark Announce License and Supply Agreement to Commercialize Prestige's Trastuzumab Biosimilar in the Russian Federation


July 08, 2019 Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige Biopharma´s Trastuzumab biosimilar in the Russian Federation.
July 2019

Prestige Biopharma partners with Mundipharma to market HD201, a trastuzumab biosimilar, in selected European countries


July 02, 2019 Prestige BioPharma announced that it has reached a licensing agreement with Mundipharma for its trastuzumab biosimilar (HD201) under which Mundipharma will have exclusive rights to distribute and market the drug in selected European markets.
June 2019

EU Investigator's Meetings for HD204 Bevacizumab Biosimilar Phase III (SAMSON-II ) in Turkey and Austria


June 26 & 28, 2019 EU Investigator's Meetings for HD204 Bevacizumab Biosimilar Phase III (SAMSON-II ) at Istanbul (Turkey) and Vienna (Austria) were completed successfully! APAC Investigator's Meeting is upcoming.
June 2019


Prestige BioPharma Reports Positive Top-Line Phase III Results for Tuznue®

June 24, 2019 Prestige BioPharma (herein, Prestige) announced positive top-line results from a Phase III global clinical trial (Troika) evaluating the efficacy, safety, and pharmacokinetics (PK) of biosimilar candidate HD201 to Herceptin (trastuzumab).
May 2019


European Medicines Agency Accepts Marketing Authorisation Application for Prestige BioPharma’s Trastuzumab Biosimilar HD201 for Review

May 28, 2019 Prestige BioPharma (herein, Prestige) announced that European Medicines Agency (EMA) has validated and accepted for review the Marketing Authorization Application (MAA) for its trastuzumab biosimilar HD201 (Tuznue®) on 23 May 2019.
May 2019
Successful EMEA Filing Submission for HD201, Herceptin Biosimilar
March 2019
Korea FDA GMP Certificate awarded to Prestige Bio Pharmaceuticals (PBK), Prestige's dedicated manufacturing facility
Mar 2019

2019 Bio Korea : Price Competitiveness is Important in the Biosimilar Market.


Michael Kim, Senior Director at Prestige, presented his key insights into winning the biosimilar market. Read it here
Dec 2018

Prestige Biopharma partners with Cipla Ltd to market key cancer biosimilar


Dec 14, 2018 Prestige BioPharma announced that it has reached a licensing agreement with Cipla Limited for its trastuzumab biosimilar (HD201) under which Cipla will have exclusive rights to distribute and market the drug in selected emerging markets.
Sep 2018

Grand Opening of Prestige Bio Pharmaceuticals Korea Osong Campus I


Sep 13, 2018 PrestigeBio Pharmaceuticals celebrated the successful completion of GMP facility, Osong Campus I, at their grand opening held September 11 in Osong, South Korea.
Jul 2018

Prestige BioPharma Singapore Initiates Listings in Korea Exchange with Samsung Securities


Jul 11, 2018 Prestige BioPharma and Samsung Securities, Korea (016360) have entered into a sponsorship and underwriting agreement for listing in Korea Exchange.
Jun 2018

Prestige BioPharma and Alvogen Announce License and Supply Agreement


Jun 28, 2018 Prestige BioPharma and Alvogen announce License and Supply Agreement: Two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma’s Trastuzumab biosimilar (HD201; Hervelous) in Central and Eastern Europe.
Feb 2018

Prestige Bio Pharma Introduces Smart Factories Platform in Korea


Feb 21, 2018 Prestige Bio Pharmaceuticals, part of the PrestigeBio Group introduces state-of-the-art process system in collaboration with Thermofisher Scientific in Korea – ‘Smart Factory Platform’.

Where You Can Find Prestige!

Aug 31-Sep 02, 2021

Event: CPhI Worldwide
Venue: Milan, Italy

June 14-17, 2021

Event: BIO 2021
Venue: Online

Jan 20-21, 2021

Event: 2021 Global IR Pitching
Venue: Online

Oct 26-28, 2020

Event: BIO-EUROPE
Venue: Virtual
Sep 18-17, 2020

Event: ESMO 2020
Venue: Virtual
Presentations: Oral & Poster
Aug 25-27, 2020

Event: CHINA BIO
Venue: Virtual
Jun 08-11, 2020

Event: BIO International Convention
Venue: Virtual
May 29-31, 2020

Event: ASCO 2020
Venue: Virtual
Presentation: Poster
Nov 5-7, 2019

Event: CPhI Worldwide
Venue: Frankfurt, Germany

Booth: 120C10
Sep 27- Oct 1, 2019

ESMO 2019
Venue: Barcelona, Spain

Booth: 316
May 31- Jun 4, 2019

Event: ASCO 2019
Venue: McCormick Place, Chicago, IL, USA

Booth: 5151
Apr 30- May 2, 2019

Event: CPhI North America
Venue: McCormick Place, Chicago, IL, USA

Booth: 1647
Apr 17 - Apr 19, 2019

Event: BioKorea 2019
Venue: COEX, Seoul, Korea
Oct 9-11, 2018

Event: BioLive Europe
Venue: IFEMA, Madrid

Booth: #12A22
Jan 8- 11, 2018

Event: J.P. Morgan Healthcare Conference
Venue: San Francisco, CA
Nov 6-8, 2017

Event: Bio-Europe
Venue: Berlin, Germany
Jun 6 - 9, 2016

Event: Bio International
Venue: San Francisco, CA
Brochure

Partnerships

그림11
그림13